GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » ZYUS Life Sciences Corp (TSXV:ZYUS) » Definitions » Net Income From Continuing Operations

ZYUS Life Sciences (TSXV:ZYUS) Net Income From Continuing Operations : C$-36.83 Mil (TTM As of Jun. 2024)


View and export this data going back to 2023. Start your Free Trial

What is ZYUS Life Sciences Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. ZYUS Life Sciences's net income from continuing operations for the three months ended in Jun. 2024 was C$-4.81 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Jun. 2024 was C$-36.83 Mil.

ZYUS Life Sciences Net Income From Continuing Operations Historical Data

The historical data trend for ZYUS Life Sciences's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ZYUS Life Sciences Net Income From Continuing Operations Chart

ZYUS Life Sciences Annual Data
Trend Dec21 Dec22 Dec23
Net Income From Continuing Operations
-23.46 -24.66 -42.59

ZYUS Life Sciences Quarterly Data
Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Net Income From Continuing Operations Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only -9.08 -4.19 -24.49 -3.34 -4.81

ZYUS Life Sciences Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-36.83 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ZYUS Life Sciences Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » ZYUS Life Sciences Corp (TSXV:ZYUS) » Definitions » Net Income From Continuing Operations
Comparable Companies
TSXV:DB XCNQ:HUGE TSX:CWEB XCNQ:GRIN TSX:MDP TSX:CRDL XCNQ:CXXI XCNQ:MMEN TSX:AVNT XCNQ:ACRG.A.U ZTS XTER:MRK TSE:4502 LSE:HLN NSE:SUNPHARMA TSE:4523 TSE:4507 SZSE:000538 XSWX:SDZ HKSE:03692
Traded in Other Exchanges
ZLSCF:USA
Address
407 Downey Road, Unit 204, Saskatoon, SK, CAN, S7N 4L8
Website
https://www.zyus.com
ZYUS Life Sciences Corp is a next-generation life sciences company engaged in scientific research and development in phyto-therapeutics, including cannabinoid and protein-based formulations. It is committed to delivering high-quality standardized therapeutic formulations that comply with Good Manufacturing Practices (GMP) to provide targeted relief for patients in Canada and globally.
Executives
John Michael Hyshka Senior Officer

ZYUS Life Sciences Headlines

No Headlines